Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cure COVID: GNS561 versus standard of care in COVID-19
2020-002249-40Phase 2Terminated
- Sponsor
- Genoscience Pharma
- Start
- May 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing GNS561 arm with Standard of care arm (2 arms). Started May 2020; status: terminated.
02
Drugs
ezurpimtrostat
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002249-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002249-40.